HANDOK INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,250 KRW | +2.08% |
|
-2.57% | -7.34% |
| Sales 2022 | 544B 394M | Sales 2023 | 523B 378M | Capitalization | 197B 142M |
|---|---|---|---|---|---|
| Net income 2022 | 10.68B 7.74M | Net income 2023 | -28.8B -20.85M | EV / Sales 2022 | 0.9 x |
| Net Debt 2022 | 258B 187M | Net Debt 2023 | 280B 203M | EV / Sales 2023 | 0.91 x |
| P/E ratio 2022 |
21.6
x | P/E ratio 2023 |
-6.84
x | Employees | 937 |
| Yield 2022 |
2.39% | Yield 2023 |
-
| Free-Float | 56.55% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.08% | ||
| 1 week | -2.57% | ||
| Current month | -6.49% | ||
| 1 month | -9.56% | ||
| 3 months | -1.85% | ||
| 6 months | +7.72% | ||
| Current year | -7.34% |
1 week
12 790.00
13 440.00
1 month
12 790.0014 500.00
Current year
12 790.0015 000.00
1 year
11 480.0015 870.00
3 years
11 480.0031 550.00
5 years
11 480.0044 750.00
10 years
11 480.0044 750.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jeong-Yeol Jo
CEO | Chief Executive Officer | 57 | - |
Young-Jin Kim
CEO | Chief Executive Officer | 67 | 83-12-31 |
Seong-Joon Hong
DFI | Director of Finance/CFO | 59 | 17-04-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Young-Jin Kim
CEO | Chief Executive Officer | 67 | 83-12-31 |
Chul-Joon Kim
BRD | Director/Board Member | 71 | 09-03-12 |
Hyun-Ik Kim
BRD | Director/Board Member | 62 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 13,250 | +2.08% | 14,528 |
| 24-04-17 | 12,980 | -0.08% | 17,453 |
| 24-04-16 | 12,990 | -1.96% | 28,497 |
| 24-04-15 | 13,250 | -1.49% | 17,670 |
| 24-04-12 | 13,450 | -1.10% | 19,698 |
End-of-day quote Korea S.E., April 17, 2024
More quotes
HANDOK Inc. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals. The Company's products include Amaryl for diabetes; Tritace for hypertension, myocardial infarction, heart failure and other cardiovascular diseases; Teveten and Triapin for essential hypertension; Munobal for hypertension and stenocardia; Ketas for disturbance of cerebral circulation; Lasix for hypertension and edema, and remedies for skin and others. It also provides over-the-counter (OTC) pharmaceuticals, healthcare products, as well as medical devices, diagnostic reagents and vaccines. In addition, the Company is involved in the real estates rental business. On July 26, 2013, it changed its name to HANDOK Inc. from Handok Pharmaceuticals Co., LTD.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.34% | 132M | |
| +27.97% | 672B | |
| +23.45% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +1.65% | 211B | |
| -0.72% | 203B | |
| -10.51% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- A002390 Stock
